Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: TREM-1 targeted therapeutics - Novo Nordisk

Drug Profile

Research programme: TREM-1 targeted therapeutics - Novo Nordisk

Alternative Names: hTREM1-IgG fusion protein - Novo Nordisk; TREM-1 - Novo Nordisk

Latest Information Update: 05 Sep 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioXell SpA
  • Developer Novo Nordisk
  • Class Proteins
  • Mechanism of Action TREM modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation; Inflammatory bowel diseases; Septic shock

Most Recent Events

  • 12 Mar 2010 BioXell SpA has been acquired and merged into Cosmo Pharmaceuticals
  • 30 Dec 2009 Novo Nordisk acquires the TREM-1 research programme from BioXell
  • 30 Dec 2009 Preclinical trials in Inflammation in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top